Positive thyroid peroxidase (TPO) antibodies with a normal TSH mean your immune system has started targeting your thyroid while the gland still keeps hormone output in range. In the 20-year Whickham Survey, euthyroid antibody positivity progressed to overt hypothyroidism at 2.1% per year (27% over 20 years), while the 13-year Busselton cohort showed risk jumps from 12.0% when baseline TSH is 2.5 mIU/L or below to 55.2% at TSH 2.5 to 4.0 and 85.7% above 4.0 mIU/L. Randomized trials (Pollock, TRUST, Feller meta-analysis, TABLET, POSTAL, T4LIFE) show levothyroxine does not improve fatigue or pregnancy live birth when TSH is normal. Care focuses on fixing iron (ferritin under 50 ng/mL), B12, celiac disease, and vitamin D, plus risk-adapted TSH tracking.
TL;DR: Positive thyroid peroxidase (TPO) antibodies with a normal TSH mean early autoimmune thyroiditis (Hashimoto's) is underway while your gland still keeps hormone levels in range:
- Your baseline TSH sets your future risk (Whickham & Busselton cohorts): Euthyroid TPOAb+ adults progress to overt hypothyroidism at 2.1% per year (27% over 20 years). In the 13-year Busselton study, risk was 12.0% when TSH <= 2.5 mIU/L, 55.2% at TSH 2.5 to 4.0, and 85.7% above 4.0 mIU/L.
- Starting levothyroxine (LT4) for fatigue when TSH is normal does not work: Across placebo-controlled trials (Pollock BMJ 2001, TRUST NEJM 2017, and the Feller JAMA 2018 meta-analysis of 21 RCTs, n = 2,192), LT4 produced zero improvement in fatigue or quality of life (SMD 0.01).
- Pre-emptive LT4 is no longer recommended for euthyroid TPOAb+ fertility or pregnancy (ATA 2026): After three null randomized trials (TABLET, POSTAL, T4LIFE), the 2026 American Thyroid Association guideline advises against starting LT4 in euthyroid TPOAb+ women (TSH < 2.5 mIU/L is the target for women already taking LT4; euthyroid women recheck TSH every 3 to 6 months when planning pregnancy).
- Fix the 4 hidden fatigue drivers that cluster with Hashimoto's: Check ferritin (target >= 50 ng/mL; TPO is an iron-dependent heme enzyme), vitamin B12 (> 400 pg/mL) + MMA and parietal cell antibodies (20% to 30% have autoimmune gastritis), celiac screening (tTG-IgA), and 25(OH) vitamin D (70 to 78 ng/mL), and consider a time-limited 3-to-6-month trial of selenomethionine 83 mcg + myo-inositol 600 mg if TSH is between 2.5 and 4.5 mIU/L.
A 36-year-old mother in Queen Village brought me two conflicting recommendations from the same month: her health-system primary care doctor saw her TSH of 1.8 mIU/L and told her that her TPO antibodies of 340 IU/mL meant nothing, while an online wellness clinic tried to sell her compounded thyroid hormone on day one. Neither doctor had checked the nutrient stores that travel alongside autoimmune thyroiditis. Her ferritin was 11 ng/mL and her vitamin B12 was 215 pg/mL with positive parietal cell antibodies - and rebuilding her iron and B12 gave her back her afternoon energy without putting her on lifelong thyroid hormone she did not need.
What does a positive thyroid antibody with a normal TSH mean?
A positive thyroid peroxidase antibody (TPOAb) with a normal TSH means your immune system has begun targeting the enzyme your thyroid uses to build hormone, even though the gland is still compensating well enough to keep blood hormone levels in range.12
In my primary care practice, this is one of the most common labs a tired patient brings me from an outside workup. Usually they were told one of two extremes: either "Your TSH is normal, so your antibodies mean nothing," or "You have Hashimoto's, so you need thyroid hormone pills immediately." Both answers miss what longitudinal cohorts show:13
| Longitudinal Cohort | Population & Follow-Up | Annual or Cumulative Progression to Hypothyroidism | How Baseline TSH & Antibodies Stratify Risk |
|---|---|---|---|
| Whickham Survey (Vanderpump et al., Clin Endocrinol 1995) | n = 2,779 UK adults followed for 20 years | ~2.1% / year (27% at 20 yrs) for antibodies alone; ~4.3% / year (55% at 20 yrs) when combined with raised TSH | Antibodies alone: OR 8 (5 to 15); antibodies + raised TSH: OR 38 (22 to 65). Men with the same risk factors had ~5x higher progression risk.12 |
| Busselton Health Study (Walsh et al., JCEM 2010) | n = 1,184 adults followed for 13 years (modern immunoassay: TPOAb > 29 kIU/L) | In TPOAb+ women over 13 years: - 12.0% at TSH <= 2.5 mIU/L - 55.2% at TSH 2.5 to 4.0 mIU/L - 85.7% at TSH > 4.0 mIU/L | Shows why a "normal" lab range of 0.45 to 4.5 mIU/L hides two distinct risk tiers above and below 2.5 mIU/L.3 |
| PREVEND & Amsterdam AITD (Roos 2010; Effraimidis 2011) | n = 2,394 (9 yrs) & n = 790 (5 yrs) euthyroid adults | 3.5% vs 0.4% (PREVEND); 4.8% at 5 yrs (Amsterdam) | Higher baseline TSH, lower baseline Free T4, and the postpartum year independently predicted progression.45 |
| TABLET Preconception Cohort (Gill et al., JCEM 2022) | n = 940 euthyroid TPOAb+ women trying to conceive | 7.4% within ~1 year (mostly before conception) | Supports checking TSH every 3 to 6 months when planning pregnancy.6 |
Why TSH = 2.5 mIU/L is the clinical dividing line (and why TPOAb matters more than TgAb)
In the Whickham logit model (Nabhan 2013 / Vanderpump 2013) and the 15,000-person Norwegian HUNT study (Åsvold et al., JCEM 2012), the probability of overt hypothyroidism stays low (1.1% over 11 years at TSH 0.5 to 1.4) until TSH crosses 2.0 to 2.5 mIU/L, climbing to 31.5% at TSH 4.0 to 4.5.740 Higher TPOAb titers (> 187 IU/mL in Feng et al., 2026) and a diffusely dark (hypoechogenic) pattern on thyroid ultrasound (Marcocci 1991) also mark higher progression risk, whereas normal ultrasound echogenicity carries very low progression risk.4142
What about thyroglobulin antibodies (TgAb)? Across Busselton, NHANES III, and an individual-participant meta-analysis of 51,138 pregnant women (Bliddal et al., Thyroid 2022), isolated TgAb positivity adds minimal risk once TPOAb is accounted for.38 TPOAb is the primary autoimmune driver to track.
Does taking levothyroxine (Synthroid) help fatigue or fertility when TSH is normal?
No (high-certainty evidence). When TSH and Free T4 are in the normal range (or mildly raised in subclinical hypothyroidism), starting levothyroxine (LT4) does not improve fatigue, mood, cognition, or pregnancy live-birth rates:91011
- Euthyroid Fatigue Crossover RCT (Pollock et al., BMJ 2001): Researchers gave 100 mcg/day of levothyroxine versus placebo for 12 weeks each to patients who had classic hypothyroid symptoms (fatigue, weight gain, cold intolerance) with normal thyroid blood tests. Levothyroxine was no better than placebo on any cognitive, psychological, or vitality score, and healthy controls felt more tired on LT4 (vitality score 60 vs 73, P < 0.01).9
- Subclinical Hypothyroidism Meta-Analysis (Feller et al., JAMA 2018, 21 RCTs, n = 2,192), TRUST (Stott et al., NEJM 2017), & Pooled TPOAb+ Analysis (Lyko et al., J Intern Med 2022): Pooling 21 randomized trials showed zero benefit from LT4 on general quality of life (SMD -0.11, 95% CI -0.25 to 0.03) or thyroid tiredness symptoms (SMD 0.01, I2 = 0%), even when restricted to patients with high baseline fatigue (de Montmollin 2020) or positive TPO antibodies (Lyko 2022, P-interaction = 0.98 for tiredness).10111243 In smaller trials (Kong 2002), LT4 worsened anxiety scores.13
- Why Autoimmune Inflammation (Not Low T4) Drives Symptoms (Guldvog et al., Ann Intern Med 2019, n = 150): In a mechanistic trial of euthyroid Hashimoto's patients with severe symptoms and TPOAb > 1,000 IU/mL despite normal hormone levels on LT4, removing the inflamed thyroid gland surgically dropped median TPOAb from 2,232 to 152 IU/mL and cut chronic fatigue from 82% to 35% (+29 points on SF-36 general health).14 Because surgery carried a 14% 5-year complication rate (recurrent laryngeal nerve injury or hypoparathyroidism), surgery is not a clinical treatment, yet it proved a key point: when TSH is normal, symptom burden comes from autoimmune inflammation and co-existing nutrient deficiencies instead of a shortage of T4 pills.1415
- Preconception, IVF, and Recurrent Pregnancy Loss (TABLET, POSTAL, T4LIFE & ATA 2026 Guidelines):
- For years, euthyroid TPOAb+ women trying to conceive were put on levothyroxine if their TSH was between 2.5 and 4.0 mIU/L. Three large randomized trials tested that practice directly and all three were null: TABLET (Dhillon-Smith et al., NEJM 2019, n = 952, live birth 37.4% vs 37.9%, RR 0.97), POSTAL (Wang et al., JAMA 2017, n = 600 IVF patients, live birth 31.7% vs 32.3%), and T4LIFE (van Dijk et al., Lancet D&E 2022, n = 187 with >= 2 pregnancy losses, live birth 50% vs 48%, RR 1.03).161718
- Based on these trials, the 2026 American Thyroid Association (ATA) Pregnancy Guideline (Korevaar et al., Thyroid 2026) and ASRM 2024 reversed earlier 2017 advice: pre-emptive LT4 should not be offered to euthyroid TPOAb+ women (even at TSH 2.5 to 4.0 mIU/L, during IVF, or after recurrent miscarriage).1920 Instead, we recheck TSH every 3 to 6 months while trying to conceive and immediately upon pregnancy confirmation. The TSH < 2.5 mIU/L (0.5 to 2.5) target applies to women already taking LT4 for hypothyroidism.19
If my thyroid hormones are in range, why am I so exhausted?
When a patient in my clinic has positive TPO antibodies, a normal TSH, and persistent exhaustion, the answer almost always turns up in one of four overlapping conditions that travel with autoimmune thyroiditis (13.5% of Hashimoto's patients have overt polyautoimmunity, Botello 2020):1521
| Co-Existing Condition | Why It Clusters With TPOAb+ Hashimoto's | Clinical Trial / Cohort Evidence | What We Order & Target at Fishtown Medicine |
|---|---|---|---|
| 1. Non-Anemic Iron Deficiency (Vaucher CMAJ 2012; Luo 2021) | Thyroid peroxidase (TPO) is a heme (iron-dependent) enzyme. Iron deficiency nearly doubles the odds of TPOAb+ (OR 1.89) and impairs T4 -> T3 deiodinase activity.2223 | In menstruating women with normal hemoglobin and ferritin < 50 ng/mL, iron cut fatigue by 47.7% vs 28.8% (Vaucher 2012; pooled SMD -0.38 in Houston 2018).2425 | Serum Ferritin + Iron/TSAT. Target ferritin >= 50 ng/mL (Hu & Rayman 2017 advise looking for gastritis/celiac if ferritin stays < 70).22 |
| 2. "Thyrogastric Syndrome" (Autoimmune Gastritis & Low B12) (Checchi 2010; Tozzoli 2010) | 20% to 30% of Hashimoto's patients carry anti-parietal cell antibodies (PCA) that attack stomach acid/intrinsic factor cells (24% develop atrophic gastritis in 5 yrs).2627 | 18% to 28% of autoimmune thyroid patients have Vitamin B12 deficiency (Ness-Abramof 2006; Benites-Zapata 2023), causing fatigue and brain fog with a normal CBC.2829 | Serum B12 + Methylmalonic Acid (MMA) (target B12 > 400 pg/mL, MMA < 260 nmol/L), plus parietal cell / intrinsic factor antibodies if iron or B12 resists oral repletion. |
| 3. Celiac Disease (Roy Thyroid 2016; Zingone Gastroenterology 2024) | Shared HLA-DQ2/DQ8 genetics: biopsy-proven celiac disease occurs in 1.6% to 2.7% of adults (and 6.2% of children) with autoimmune thyroiditis.3031 | Silent villous atrophy causes malabsorption of iron, B12, selenium, and vitamin D without classic diarrhea. | Tissue Transglutaminase IgA (tTG-IgA) + Total IgA (while still eating gluten; see celiac testing guide).31 |
| 4. Vitamin D Insufficiency & Autoimmune Cytokines (Luo 2024; Alfì 2026) | Low 25(OH)D tracks with higher TPOAb titers; separately, TPOAb > 121 IU/mL correlates with lower SF-36 vitality independent of TSH/FT3.1532 | Vitamin D supplementation (> 3 months in deficient patients) lowers TPOAb (SMD -1.1), though Mendelian randomization shows 25(OH)D alone rarely explains fatigue.3233 | 25(OH) Vitamin D (target 70 to 78 ng/mL), plus screening for sleep disorders, RED-S under-fueling, or morning cortisol if clinical features point there. |
Get Real Answers
Tired of being told your labs are 'normal'? Dr. Ash digs deeper.
What do clinical trials show for selenium and myo-inositol?
Because the thyroid holds more selenium per gram than any other organ (using selenoproteins like glutathione peroxidase GPx and iodothyronine deiodinases DIO1/DIO2 to neutralize hydrogen peroxide during hormone synthesis), selenium is the most widely studied micronutrient in Hashimoto's.2234
Recent meta-analyses and randomized trials draw a clear boundary between changing lab numbers and changing how you feel:
- Selenium lowers TPO antibodies and slightly nudges untreated TSH, without improving fatigue (Huwiler et al., Thyroid 2024, 35 RCTs; CATALYST Trial): Across 35 randomized trials, selenium lowered TPOAb (SMD -0.96, I2 = 90%, low certainty) and slightly lowered TSH in patients not on levothyroxine (SMD -0.21, I2 = 0%, moderate certainty), with no change in Free T4 or Free T3.34 However, in untreated euthyroid adults (Esposito et al., 2017, 166 mcg/d selenomethionine for 6 months) and in the Danish CATALYST RCT (200 mcg/d for 12 months), selenium did not improve thyroid quality-of-life scores or prevent progression to hypothyroidism.3435
- Adding myo-inositol (600 mg) to selenomethionine (83 mcg) when TSH is borderline (2.5 to 6.0 mIU/L): Myo-inositol generates the intracellular second messenger (IP3) that helps the thyroid respond to TSH. In Italian trials (Nordio & Pajalich 2013, n = 48; Nordio & Basciani 2017, n = 168) and a 2026 meta-analysis (Stanchev et al., J Clin Med 2026, n = 288), combining myo-inositol 600 mg + selenomethionine 83 mcg lowered borderline TSH by ~31% (SMD -1.26) compared with selenium alone (though trials were small and mostly unblinded).3637
- Why you should never megadose selenium (NPC Trial Diabetes Signal): More selenium is not better. The European Food Safety Authority (EFSA) tolerable upper limit is 255 mcg/day, and supplementation is unnecessary when serum selenium is already >= 122 mcg/L (common in North America).34 In the randomized Nutritional Prevention of Cancer (NPC) trial (Stranges et al., Annals of Internal Medicine 2007), taking 200 mcg/day of selenium for 7.7 years in a selenium-replete US cohort increased incident Type 2 Diabetes by 55% (HR 1.55, and HR 2.70 in the highest baseline selenium tertile) (meta-analysis RR 1.11, Vinceti 2018).3839
How we structure your surveillance and treatment plan at Fishtown Medicine
- Run the complete baseline workup once: TSH, Free T4, Free T3, TPOAb, ferritin + iron panel, Vitamin B12 + MMA, tTG-IgA + total IgA, and 25(OH)D (we do not routinely repeat TPOAb every few months once positivity is established, because antibody swings do not dictate medication dosing).322
- Fix every non-thyroid fatigue driver first: Replete iron until ferritin is >= 50 ng/mL, bring B12 above 400 pg/mL (MMA < 260 nmol/L), and bring 25(OH)D to 70 to 78 ng/mL.2224
- If TSH is between 2.5 and 4.5 mIU/L, consider a time-limited 3-to-6-month trial of selenomethionine 83 mcg + myo-inositol 600 mg/day: Recheck TSH at 6 months and stop if TSH does not move or if you are already selenium-replete (and skip selenium in pregnancy per ATA 2026 guidelines).193436
- Match TSH surveillance to your risk tier:
- TSH 1.0 to 2.5 mIU/L (12% 13-yr risk): Recheck TSH and Free T4 every 12 to 24 months.3
- TSH 2.5 to 4.5 mIU/L (55% 13-yr risk): Recheck TSH and Free T4 every 6 to 12 months.3
- Planning pregnancy or postpartum (7.4% 1-yr risk): Recheck TSH every 3 to 6 months preconception, upon a positive pregnancy test, and at 6 weeks and 6 months postpartum (fourth-trimester workup).619
- If TSH rises persistently above 4.5 to 7.0+ mIU/L or Free T4 drops: That is the clear inflection point to start individualized thyroid replacement (thyroid optimization guide).
Guidance from the Clinic
Key Takeaways
- Euthyroid TPOAb+ progresses to overt hypothyroidism at ~2.1%/year (Whickham Survey), with 13-year risk stratified sharply by baseline TSH in Busselton: 12.0% at TSH <= 2.5, 55.2% at TSH 2.5 to 4.0, and 85.7% above 4.0 mIU/L.13
- Levothyroxine (LT4) does not improve fatigue in euthyroid or mildly subclinical patients (Pollock 2001; TRUST 2017; Feller JAMA 2018 meta-analysis SMD 0.01) and does not improve live birth in euthyroid TPOAb+ preconception/IVF/miscarriage trials (TABLET, POSTAL, T4LIFE; ATA 2026 guideline).9111619
- Look for the 4 co-existing fatigue drivers first: Non-anemic iron deficiency (ferritin < 50 ng/mL, -47.7% fatigue when repleted), autoimmune gastritis / low B12 (18% to 28%), celiac disease (1.6% to 2.7%), and vitamin D insufficiency.24262930
- Keep selenium time-limited (83 to 100 mcg/d ± myo-inositol 600 mg/d for 3 to 6 months): Avoid multi-year 200 mcg/d dosing in selenium-replete adults due to the NPC trial diabetes signal (HR 1.55).343738
Related at Fishtown Medicine
- Hashimoto's Thyroiditis: Full Clinical Guide to Labs, TSH Targets, and Levothyroxine - how we manage Hashimoto's once TSH rises or levothyroxine is started
- 9-System Biomarker Reference Guide: Optimal vs Standard Lab Ranges - optimal targets for TSH, Free T3/T4, ferritin, B12, MMA, and vitamin D across all 9 systems
- Thyroid Optimization Guide - how TSH, Free T4, Free T3, and antibodies work together
- Tired for Months: A Deeper Fatigue Workup - evaluating non-anemic iron deficiency and B12 depletion alongside thyroid function
- Autoimmune Gastritis and Iron Deficiency - why Hashimoto thyroiditis and low ferritin/B12 travel together
Scientific References
- Vanderpump MP, Tunbridge WM, French JM, et al. "The Incidence of Thyroid Disorders in the Community: A Twenty-Year Follow-Up of the Whickham Survey." Clinical Endocrinology. 1995;43(1):55-68. PubMed
- Dayan CM, Daniels GH. "Chronic Autoimmune Thyroiditis." New England Journal of Medicine. 1996;335(2):99-107. DOI
- Walsh JP, Bremner AP, Feddema P, Michelangeli VP, Leedman PJ. "Thyrotropin and Thyroid Antibodies as Predictors of Hypothyroidism: A 13-Year, Longitudinal Study of a Community-Based Cohort Using Current Immunoassay Techniques." Journal of Clinical Endocrinology & Metabolism. 2010;95(3):1095-1104. PubMed
- Roos A, Links TP, de Jong-van den Berg LT, et al. "Thyroid Peroxidase Antibodies, Levels of Thyroid Stimulating Hormone and Development of Hypothyroidism in Euthyroid Subjects." European Journal of Internal Medicine. 2010;21(6):555-559. PubMed
- Effraimidis G, Strieder TG, Tijssen JG, Wiersinga WM. "Natural History of the Transition From Euthyroidism to Overt Autoimmune Hypo- or Hyperthyroidism: A Prospective Study." European Journal of Endocrinology. 2011;164(1):107-113. PubMed
- Gill S, Cheed V, Morton VAH, et al. "Evaluating the Progression to Hypothyroidism in Preconception Euthyroid Thyroid Peroxidase Antibody-Positive Women." Journal of Clinical Endocrinology & Metabolism. 2022;107(11):3120-3129. PubMed
- Nabhan F, Porter K, Kloos RT; Vanderpump M, French J. "Predicting Hypothyroidism From the Whickham Survey." Clinical Endocrinology. 2013;78(3):478-479. DOI
- Bliddal S, Derakhshan A, Xiao Y, et al. "Association of Thyroid Peroxidase Antibodies and Thyroglobulin Antibodies With Thyroid Function in Pregnancy: An Individual Participant Data Meta-Analysis." Thyroid. 2022;32(7):828-840. DOI
- Pollock MA, Sturrock A, Marshall K, et al. "Thyroxine Treatment in Patients With Symptoms of Hypothyroidism but Thyroid Function Tests Within the Reference Range: Randomised Double Blind Placebo Controlled Crossover Trial." BMJ. 2001;323(7318):891-895. PubMed
- Stott DJ, Rodondi N, Kearney PM, et al. "Thyroid Hormone Therapy for Older Adults With Subclinical Hypothyroidism" (TRUST). New England Journal of Medicine. 2017;376(26):2534-2544. DOI
- Feller M, Snel M, Moutzouri E, et al. "Association of Thyroid Hormone Therapy With Quality of Life and Thyroid-Related Symptoms in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis." JAMA. 2018;320(13):1349-1359. DOI
- de Montmollin M, Feller M, Beglinger S, et al. "L-Thyroxine Therapy for Older Adults With Subclinical Hypothyroidism and Hypothyroid Symptoms: Secondary Analysis of a Randomized Trial." Annals of Internal Medicine. 2020;172(11):709-716. PubMed
- Kong WM, Sheikh MH, Lumb PJ, et al. "A 6-Month Randomized Trial of Thyroxine Treatment in Women With Mild Subclinical Hypothyroidism." American Journal of Medicine. 2002;112(5):348-354. PubMed
- Guldvog I, Reitsma LC, Johnsen L, et al. "Thyroidectomy Versus Medical Management for Euthyroid Patients With Hashimoto Disease and Persisting Symptoms: A Randomized Trial." Annals of Internal Medicine. 2019;170(7):453-464. PubMed
- Alfì G, Caruso V, Grenno G, et al. "Hashimoto's Thyroiditis Beyond Thyroid Hormones: A Systematic Review of Autoimmunity, Inflammation, and Multidimensional Burden." Clinical Endocrinology. 2026. DOI
- Dhillon-Smith RK, Middleton LJ, Sunner KK, et al. "Levothyroxine in Women With Thyroid Peroxidase Antibodies Before Conception" (TABLET). New England Journal of Medicine. 2019;380(14):1316-1325. DOI
- Wang H, Gao H, Chi H, et al. "Effect of Levothyroxine on Miscarriage Among Women With Normal Thyroid Function and Thyroid Autoimmunity Undergoing In Vitro Fertilization and Embryo Transfer" (POSTAL). JAMA. 2017;318(22):2190-2198. DOI
- van Dijk MM, Vissenberg R, Fliers E, et al. "Levothyroxine in Euthyroid Thyroid Peroxidase Antibody Positive Women With Recurrent Pregnancy Loss (T4LIFE Trial): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial." The Lancet Diabetes & Endocrinology. 2022;10(5):322-329. PubMed
- Korevaar TIM, Leung AM, Alexander EK, et al. "American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum." Thyroid. 2026. DOI
- Practice Committee of the American Society for Reproductive Medicine (ASRM). "Subclinical Hypothyroidism in the Infertile Female Population: A Guideline." Fertility and Sterility. 2024.
- Botello A, Herrán M, Salcedo V, et al. "Prevalence of Latent and Overt Polyautoimmunity in Autoimmune Thyroid Disease: A Systematic Review and Meta-Analysis." Clinical Endocrinology. 2020;93(4):375-389. DOI
- Hu S, Rayman MP. "Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis." Thyroid. 2017;27(5):597-610. DOI
- Luo J, Wang X, Yuan L, Guo L. "Iron Deficiency, a Risk Factor of Thyroid Disorders in Reproductive-Age and Pregnant Women: A Systematic Review and Meta-Analysis." Frontiers in Endocrinology. 2021;12:629831. PubMed
- Vaucher P, Druais PL, Waldvogel S, Favrat B. "Effect of Iron Supplementation on Fatigue in Nonanemic Menstruating Women With Low Ferritin: A Randomized Controlled Trial." CMAJ. 2012;184(11):1247-1254. PubMed
- Houston BL, Hurrie D, Graham J, et al. "Efficacy of Iron Supplementation on Fatigue and Physical Capacity in Non-Anaemic Iron-Deficient Adults: A Systematic Review of Randomised Controlled Trials." BMJ Open. 2018;8(4):e019240. PubMed
- Checchi S, Montanaro A, Ciuoli C, et al. "Prevalence of Parietal Cell Antibodies in a Large Cohort of Patients With Autoimmune Thyroiditis." Thyroid. 2010;20(12):1385-1389. DOI
- Tozzoli R, Kodermaz G, Perosa AR, et al. "Autoantibodies to Parietal Cells as Predictors of Atrophic Body Gastritis: A Five-Year Prospective Study in Patients With Autoimmune Thyroid Diseases." Autoimmunity Reviews. 2010;10(2):80-83. PubMed
- Ness-Abramof R, Nabriski DA, Braverman LE, et al. "Prevalence and Evaluation of B12 Deficiency in Patients With Autoimmune Thyroid Disease." American Journal of the Medical Sciences. 2006;332(3):119-122. PubMed
- Benites-Zapata VA, Ignacio-Cconchoy FL, Ulloque-Badaracco JR, et al. "Vitamin B12 Levels in Thyroid Disorders: A Systematic Review and Meta-Analysis." Frontiers in Endocrinology. 2023;14:1070592. PubMed
- Roy A, Laszkowska M, Sundström J, et al. "Prevalence of Celiac Disease in Patients With Autoimmune Thyroid Disease: A Meta-Analysis." Thyroid. 2016;26(7):880-890. DOI
- Zingone F, Bai JC, Cellier C, Ludvigsson JF. "Celiac Disease-Related Conditions: Who to Test?" Gastroenterology. 2024;167(1):64-78. PubMed
- Luo D, Li B, Shan Z, et al. "The Impacts of Vitamin D Supplementation on Serum Levels of Thyroid Autoantibodies in Patients With Autoimmune Thyroid Disease: A Meta-Analysis." PeerJ. 2024. PubMed
- Havdahl A, Mitchell R, Paternoster L, Davey Smith G. "Investigating Causality in the Association Between Vitamin D Status and Self-Reported Tiredness." Scientific Reports. 2019;9:2880. DOI
- Huwiler VV, Maissen-Abgottspon S, Stanga Z, et al. "Selenium Supplementation in Patients With Hashimoto Thyroiditis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials." Thyroid. 2024;34(3):295-313. PubMed
- Esposito D, Rotondi M, Accardo G, et al. "Influence of Short-Term Selenium Supplementation on the Natural Course of Hashimoto's Thyroiditis: Clinical Results of a Blinded Placebo-Controlled Randomized Prospective Trial." Journal of Endocrinological Investigation. 2017;40(1):83-89. PubMed
- Nordio M, Basciani S. "Myo-Inositol Plus Selenium Supplementation Restores Euthyroid State in Hashimoto's Patients With Subclinical Hypothyroidism." European Review for Medical and Pharmacological Sciences. 2017;21(2 Suppl):51-59. PubMed
- Stanchev P, Kraeva M, Petrov PP, Penchev P. "Myo-Inositol Plus Selenium vs. Selenium Alone in Hashimoto's Thyroiditis With Subclinical Hypothyroidism: A Systematic Review and Updated Meta-Analysis With Trial Sequential Analysis." Journal of Clinical Medicine. 2026. PubMed
- Stranges S, Marshall JR, Natarajan R, et al. "Effects of Long-Term Selenium Supplementation on the Incidence of Type 2 Diabetes: A Randomized Trial." Annals of Internal Medicine. 2007;147(4):217-223. PubMed
- Vinceti M, Filippini T, Rothman KJ. "Selenium Exposure and the Risk of Type 2 Diabetes: A Systematic Review and Meta-Analysis." European Journal of Epidemiology. 2018;33(9):789-810. PubMed
- Åsvold BO, Vatten LJ, Midthjell K, Bjøro T. "Serum TSH Within the Reference Range as a Predictor of Future Hypothyroidism and Hyperthyroidism: 11-Year Follow-Up of the HUNT Study in Norway." Journal of Clinical Endocrinology & Metabolism. 2012;97(1):93-99. PubMed
- Feng X, Lyu X, Gao Y, Gao X, Gao R. "Analysis of Risk Factors for Hypothyroidism in Initially Euthyroid Patients With Positive Thyroid Autoantibodies: A Multicenter Retrospective Cohort Study." Frontiers in Endocrinology. 2026. PubMed
- Marcocci C, Vitti P, Cetani F, et al. "Thyroid Ultrasonography Helps to Identify Patients With Diffuse Lymphocytic Thyroiditis Who Are Prone to Develop Hypothyroidism." Journal of Clinical Endocrinology & Metabolism. 1991;72(1):209-213. PubMed
- Lyko C, Blum MR, Abolhassani N, et al. "Thyroid antibodies and levothyroxine effects in subclinical hypothyroidism: A pooled analysis of two randomized controlled trials." Journal of Internal Medicine. 2022;292(6):892-903. DOI
- Petri M, Karlson EW, Cooper DS, Ladenson PW. "Autoantibody tests in autoimmune thyroid disease: a case-control study." The Journal of Rheumatology. 1991;18(10):1529-1534. PubMed
- Tektonidou MG, Anapliotou M, Vlachoyiannopoulos P, Moutsopoulos HM. "Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases." Annals of the Rheumatic Diseases. 2004;63(9):1159-1161. PubMed

Fishtown Medicine | Symptoms
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.




